A Randomized Phase 2 Trial of Cediranib and Olaparib Compared to Bevacizumab in Patients With Recurrent Glioblastoma Who Have Not Received Prior VEGF Therapy
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2017
At a glance
- Drugs Cediranib (Primary) ; Olaparib (Primary) ; Bevacizumab
- Indications Glioblastoma
- Focus Therapeutic Use
- 29 Sep 2017 Planned End Date changed from 30 Sep 2019 to 31 Oct 2019.
- 29 Sep 2017 Planned primary completion date changed from 30 Sep 2019 to 31 Oct 2019.
- 29 Sep 2017 Status changed from not yet recruiting to recruiting.